Business Description
BioCryst Pharmaceuticals Inc
NAICS : 325414
SIC : 2836
ISIN : US09058V1035
Description
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.47 | |||||
Equity-to-Asset | -0.88 | |||||
Debt-to-Equity | -1.81 | |||||
Debt-to-EBITDA | -7.09 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -3.3 | |||||
Beneish M-Score | -3.57 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 153.4 | |||||
3-Year EBITDA Growth Rate | 15.5 | |||||
3-Year EPS without NRI Growth Rate | 2.3 | |||||
3-Year FCF Growth Rate | 14.6 | |||||
3-Year Book Growth Rate | -172.8 | |||||
Future 3-5Y Total Revenue Growth Rate | 12 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 24.36 | |||||
9-Day RSI | 32.18 | |||||
14-Day RSI | 35.92 | |||||
6-1 Month Momentum % | -6.29 | |||||
12-1 Month Momentum % | -28.44 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.31 | |||||
Quick Ratio | 3.12 | |||||
Cash Ratio | 2.59 | |||||
Days Inventory | 2198.07 | |||||
Days Sales Outstanding | 58.92 | |||||
Days Payable | 1033.04 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -5.2 | |||||
Shareholder Yield % | -28.04 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 98.59 | |||||
Operating Margin % | -31.29 | |||||
Net Margin % | -68.36 | |||||
FCF Margin % | -29.36 | |||||
ROA % | -43.08 | |||||
ROIC % | -184.59 | |||||
ROC (Joel Greenblatt) % | -569.1 | |||||
ROCE % | -28.03 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 2.57 | |||||
EV-to-EBIT | -11.44 | |||||
EV-to-Forward-EBIT | 65.77 | |||||
EV-to-EBITDA | -11.6 | |||||
EV-to-Revenue | 4.07 | |||||
EV-to-Forward-Revenue | 3.39 | |||||
EV-to-FCF | -13.87 | |||||
Price-to-Median-PS-Value | 0.15 | |||||
Earnings Yield (Greenblatt) % | -8.74 | |||||
FCF Yield % | -10.66 |